Literature DB >> 2253195

Glycosphingolipids of human gliomas.

R Jennemann1, A Rodden, B L Bauer, H D Mennel, H Wiegandt.   

Abstract

Histologically characterized human gliomas of various grades of malignancy obtained during surgery were extracted, and their glycolipids were isolated and partially identified. Among the gliomas analyzed, three types of glycolipid component distribution could be identified. The glycosphingolipid (GSL) type I pattern correlated closely with that of the most malignant gliomas (Grade IV). Its neutral GSLs consisted of glucosyl- and, as a major component, dihexosylceramide, in addition to globo- and neolactotetraosylceramide. Galactosylceramide and sulfatide were absent. The gangliosides of GSL type I were almost exclusively of the GLac family, aside from small amounts of neolacto-series-derived species. The neutral components of GSL type II were similar to those of GSL type I. The acidic compounds of GSL type II were gangliosides of the Gtri family and trace amounts of neolacto-series sialoglycolipids, in addition to GLac1 and GLac2. GSL type II contained no Gtet gangliosides and no sulfatide. The GSL type III pattern was that of the most benign gliomas, with all glycolipids present that are found in normal brain and, in addition, those of the GSL type II.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253195

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Plasma membrane-associated glycohydrolases activation by extracellular acidification due to proton exchangers.

Authors:  Massimo Aureli; Nicoletta Loberto; Rosaria Bassi; Anita Ferraretto; Silvia Perego; Patrizia Lanteri; Vanna Chigorno; Sandro Sonnino; Alessandro Prinetti
Journal:  Neurochem Res       Date:  2012-02-23       Impact factor: 3.996

2.  Growth inhibition and induction of differentiation and apoptosis mediated by sodium butyrate in Caco-2 cells with algal glycolipids.

Authors:  Zakir Hossain; Hideyuki Kurihara; Masashi Hosokawa; Koretaro Takahashi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 May-Jun       Impact factor: 2.416

3.  Sex- and age-related differences in ceramide dihexosides of primary human brain tumors.

Authors:  A J Yates; T K Franklin; B W Scheithauer; P C Burger; D K Pearl
Journal:  Lipids       Date:  1999-01       Impact factor: 1.880

4.  Discrimination of human astrocytoma subtypes by lipid analysis using desorption electrospray ionization imaging mass spectrometry.

Authors:  Livia S Eberlin; Allison L Dill; Alexandra J Golby; Keith L Ligon; Justin M Wiseman; R Graham Cooks; Nathalie Y R Agar
Journal:  Angew Chem Int Ed Engl       Date:  2010-08-09       Impact factor: 15.336

5.  Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth.

Authors:  Richard Jennemann; Roger Sandhoff; Shijun Wang; Eva Kiss; Norbert Gretz; Cecilia Zuliani; Ana Martin-Villalba; Richard Jäger; Hubert Schorle; Marc Kenzelmann; Mahnaz Bonrouhi; Herbert Wiegandt; Hermann-Josef Gröne
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-18       Impact factor: 11.205

6.  Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.

Authors:  S Ohta; A Honda; Y Tokutake; H Yoshida; N Hanai
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Glycosphingolipid component profiles of human gliomas correlate with histological tumour types: analysis of inter-individual and tumour-regional distribution.

Authors:  R Jennemann; H D Mennel; B L Bauer; H Wiegandt
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  A rapid method for the preparation of ganglioside Glac2 (GD3).

Authors:  R Jennemann; H Wiegandt
Journal:  Lipids       Date:  1994-05       Impact factor: 1.880

9.  Gangliosides in meningiomas: correlation of Glac2 to intermediary filament.

Authors:  G Pausch; R Jennemann; H D Mennel; B L Bauer; A F Rodden; H Wiegandt
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

10.  A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.

Authors:  K Shitara; Y Kuwana; K Nakamura; Y Tokutake; S Ohta; H Miyaji; M Hasegawa; N Hanai
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.